@aruc6393 thank you for your excellent posts; particularly the...

@aruc6393 thank you for your excellent posts; particularly the above, which clarified the significance of yesterday's announcement. i can only speak for myself, but i am was so tuned into what PIQ is doing

it seems what you explained (Immunoassay technology vs Mass Spectrometry Units) was clearly explained in the Annual Report, which I will post so half-asleep folks, such as myself, can get up to speed with things.



Dear Fellow Shareholder,

The 2018-19 financial year has been one of consolidation and realignment for Proteomics International Laboratories Ltd, in which the Company has moved significantly further towards broadscale commercialisation of its flagship diagnostic product,the pioneering PromarkerD test for diabetic kidney disease.

Having clearly established the science behind PromarkerDthrough peer reviewed clinical studies we are all aware that the next steps in the commercialisation process are adoption of the test by pathology laboratories around the world.

The protein biomarkers applicable to PromarkerD were discovered and developed using a technique called Mass Spectrometry, which requires sophisticated equipment and a high degree of expertise, only available in specialist pathology laboratories. Consequently, enormous effort has been spent this year in developing a so-called Immunoassay In Vitro Diagnostic (IVD) method, which can be readily used by the majority of laboratories worldwide. This process is now in its finalstages and described in detail in our 2019 Annual Report Review of Operations.

The PromarkerD test is now more versatile and marketable, with the different technology platforms offering more opportunities for future licensing deals.We continue our commercialisation efforts, and dialogue with potential licensees in the huge markets of Europe, Japan, India and US. The execution of transformational licensing agreements with tier-1 diagnostics and pharmaceutical companies remains the key focus for Proteomics International in FY2020.

[also]

It is important to note too, that Janssen Pharmaceuticals, a division of Johnson and Johnson, have now demonstrated there is a class of drug (gliflozins) able to treat diabetic kidney disease once diagnosed. It is this drug which we are testing in collaboration with our strategic partner Janssen Research and Development. The results from this exciting collaborative study are due late this calendar year. If a successful correlation can be established, PromarkerD may become a Complementary Diagnostic (CDx) for such drugs, potentially being utilised every time a prescription is issued.

Part of our ongoing strategy is to develop further tests where we see there is a significant unmet medical need - we have discovered new potential biomarkers to test for endometriosis, a painful condition that affects one in ten women in their reproductive years, and for the Giardia parasite,which is the leading cause of gastroenteritis worldwide, both of which are currently difficult to diagnose. These two indications each present a significant opportunity for Proteomics International and further developments will take place during the next few months.

ProteomicsInternational has also experienced significant growth in analytical services revenue, led by continued volume in biosimilars and pharmacokinetic testing, as well as specialist analytical work. This includes some of our largest-ever contracts. We recognise that the pathway to PromarkerD’s commercialsuccess has been longer than estimated, but we are confident that all the elements are nowin place and progressing well.

We thank our shareholders for their patience -with PromarkerD being evaluated by global pharmaceutical and diagnostics companies, biomarker studies for new diseases in the pipeline, and an increasing revenue base, we look forward to a transformative year ahead.